Novo Nordisk Withdraws Its Application To Extend The Marketing Authorisations For NovoNorm And Prandin

Thu, 19 Oct 2006 04:00 AM EST

... The European Medicines Agency has been formally notified by Novo Nordisk A/S of its decision to withdraw its application for a change to the marketing authorisations for NovoNorm (repaglinide) and Prandin (repaglinide) 0.5 mg, 1 mg and 2 mg tablets. NovoNorm was first authorised in the European Union on 17 August 1998 and Prandin on 29 January 2001. [click link for full article] ...